[{"orgOrder":0,"company":"IRICoR","sponsor":"Universite de Montreal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"IRICoR","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRICoR \/ Universite de Montreal","highestDevelopmentStatusID":"3","companyTruncated":"IRICoR \/ Universite de Montreal"},{"orgOrder":0,"company":"AbCellera","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Biogen"},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyclica \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration aims to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 03, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Biogen

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration builds on research from the team of Dr. Daniel Levesque at UdeM, and focuses on the design of highly selective modulators of the Nur77/RXR nuclear receptor complex, a promising new pharmacological target for movement disorders.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 03, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Universite de Montreal

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 27, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Cerevel Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proprietary platform combines industry-leading technologies from partners AbCellera, Twist Bioscience and WuXi Biologics to develop fully species-specific, optimized and half-life-extended monoclonal antibodies (mABs) for veterinary use.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          July 16, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery Platform

                          Sponsor : Invetx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank